Jeff Walsh

Jeff joined Nvelop as CEO in April of 2023. He brings over 30 years of experience in leadership positions with public and private life sciences companies. Prior to Nvelop, Jeff was a venture partner at Third Rock Ventures, evaluating next gen gene and cell therapy opportunities. Prior to TRV, he held executive roles at bluebird bio from 2011-2020, including chief financial and strategy officer and chief operating officer. Jeff previously served as chief business and financial officer of Taligen Therapeutics, Inc. through its sale to Alexion Pharmaceuticals. He also held business development and finance roles at Pathogenesis (sold to Chiron), EXACT Sciences, Allscripts and SmithKline Beecham.

Jeff currently serves on the Board of Directors at Tenaya Therapeutics and Tevard Biosciences and is an Executive Teaching Fellow at Boston University’s Questrom School of Business. He received his B.A. from Yale University and M.B.A. from the Kellogg Graduate School of Management at Northwestern University.

Favorite Activity: Traveling and playing tennis with his wife and three daughters while also sneaking in a round of bad golf.